BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 34078123)

  • 1. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
    Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
    Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
    [No Abstract]   [Full Text] [Related]  

  • 2. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.
    Min IM; Shevlin E; Vedvyas Y; Zaman M; Wyrwas B; Scognamiglio T; Moore MD; Wang W; Park S; Park S; Panjwani S; Gray KD; Tassler AB; Zarnegar R; Fahey TJ; Jin MM
    Clin Cancer Res; 2017 Dec; 23(24):7569-7583. PubMed ID: 29025766
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 4. PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.
    Gray KD; McCloskey JE; Vedvyas Y; Kalloo OR; Eshaky SE; Yang Y; Shevlin E; Zaman M; Ullmann TM; Liang H; Stefanova D; Christos PJ; Scognamiglio T; Tassler AB; Zarnegar R; Fahey TJ; Jin MM; Min IM
    Clin Cancer Res; 2020 Nov; 26(22):6003-6016. PubMed ID: 32887724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells.
    Cooney CA; Jousheghany F; Yao-Borengasser A; Phanavanh B; Gomes T; Kieber-Emmons AM; Siegel ER; Suva LJ; Ferrone S; Kieber-Emmons T; Monzavi-Karbassi B
    Breast Cancer Res; 2011 Jun; 13(3):R58. PubMed ID: 21658254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
    Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
    [No Abstract]   [Full Text] [Related]  

  • 7. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
    Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
    Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
    JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitor of apoptosis protein Livin promotes tumor progression and chemoradioresistance in human anaplastic thyroid cancer.
    Kim HK; Kim SA; Jung EK; Lee KH; Lee JK; Kang HC; Joo YE; Lim SC; Yoon TM
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
    Hsu SC; Nadesan P; Puviindran V; Stallcup WB; Kirsch DG; Alman BA
    J Biol Chem; 2018 Feb; 293(7):2466-2475. PubMed ID: 29196603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
    Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
    Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
    [No Abstract]   [Full Text] [Related]  

  • 12. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma.
    Rivera Z; Ferrone S; Wang X; Jube S; Yang H; Pass HI; Kanodia S; Gaudino G; Carbone M
    Clin Cancer Res; 2012 Oct; 18(19):5352-63. PubMed ID: 22893632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
    Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
    Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
    [No Abstract]   [Full Text] [Related]  

  • 14. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
    Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell Cycle M-Phase Genes Are Highly Upregulated in Anaplastic Thyroid Carcinoma.
    Weinberger P; Ponny SR; Xu H; Bai S; Smallridge R; Copland J; Sharma A
    Thyroid; 2017 Feb; 27(2):236-252. PubMed ID: 27796151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
    Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
    J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.
    Bastman JJ; Serracino HS; Zhu Y; Koenig MR; Mateescu V; Sams SB; Davies KD; Raeburn CD; McIntyre RC; Haugen BR; French JD
    J Clin Endocrinol Metab; 2016 Jul; 101(7):2863-73. PubMed ID: 27045886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.
    Leuci V; Donini C; Grignani G; Rotolo R; Mesiano G; Fiorino E; Gammaitoni L; D'Ambrosio L; Merlini A; Landoni E; Medico E; Capellero S; Giraudo L; Cattaneo G; Iaia I; Pignochino Y; Basiricò M; Vigna E; Pisacane A; Fagioli F; Ferrone S; Aglietta M; Dotti G; Sangiolo D
    Clin Cancer Res; 2020 Dec; 26(23):6321-6334. PubMed ID: 32900797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells.
    Wennerberg E; Pfefferle A; Ekblad L; Yoshimoto Y; Kremer V; Kaminskyy VO; Juhlin CC; Höög A; Bodin I; Svjatoha V; Larsson C; Zedenius J; Wennerberg J; Lundqvist A
    Clin Cancer Res; 2014 Nov; 20(22):5733-44. PubMed ID: 25212604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.